Skip to content

Inhibrx Biosciences, Inc. INBX Nonmonetary Transaction, Gain (Loss) Recognized on Transfer

Discontinued — last reported Q4 '25

Nonmonetary Transaction, Gain (Loss) Recognized on Transfer at other companies

Trupanion logo
TrupanionTRUP
$1.95M
AMB
Ambiq Micro, Inc.AMBQ
$0-100%
Hagerty logo
HagertyHGTY
-$213K+81.3%
JAN
Janus Living JAN
$93.5K-63.3%
First Financial Bankshares logo
First Financial BanksharesFFIN
-$56K-60.0%
Noble Corporation logo
Noble CorporationNE
$89.86M

Segments

By segment

See full
Reportable Segment$0-100%

Other financials

Income statement

See full
Revenue--100%
Operating income-$30.9M+27.9%
Net income-$33.4M+22.8%
EPS (diluted)-$2.15+23.2%

Balance sheet

See full
Cash & equivalents$161.7M-25.3%
Total debt$180.9M+69.8%
Total equity-$21.0M-122%
Total assets$184.0M-24.2%

Cash flow

See full
Operating cash flow-$38.0M-5.9%
CapEx--100%
Free cash flow-$38.0M-5.9%

Valuation

See full
Market cap$1.4B+547%
Enterprise value$1.42B+1,236%
P/S1,073.7×-280×

Profitability

See full
Operating margin-10,386.5%-5,025pp
Net margin-10,773.5%-878,492pp
FCF margin-9,986.5%-4,727pp

Returns & leverage

See full
Return on equity-197.8%-2,158pp
Debt / equity13.4×+13.3×
Current ratio6.5×+1.3×

Where this comes from

Reported directly by Inhibrx Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NonmonetaryTransactionGainLossRecognizedOnTransfer.

The official record: Inhibrx Biosciences, Inc.’s 10-K, filed March 19, 2026, on SEC EDGAR. View the filing →

Ask your AI about Inhibrx Biosciences, Inc.'s nonmonetary transaction, gain (loss) recognized on transfer.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Inhibrx Biosciences, Inc.'s nonmonetary transaction, gain (loss) recognized on transfer?
Inhibrx Biosciences, Inc. (INBX) reported nonmonetary transaction, gain (loss) recognized on transfer of $0 in Q4 2025.
What does nonmonetary transaction, gain (loss) recognized on transfer mean?
This metric represents the net gain or loss recognized from the exchange of non-cash assets or liabilities, such as equipment, intellectual property, or equity interests. It reflects the impact of non-routine transactions on the company's operating results, excluding standard cash-based operational activities. Investors monitor this to isolate the impact of asset divestitures or strategic exchanges from core research and development performance.